Alzheimer’s Association: Part the Cloud – Enable the Molecule for Therapeutics Funding Program

If you are interested in this opportunity, please contact Carole King at carole.king@med.usc.edu.

• LOI due: August 6, 2025
• Amount up to $1,000,000 (including 10% indirects)
• Project period up to 3 years

Funds to advance promising Alzheimer’s and related disorders therapeutics through final stages of investigational new drug (IND) -enabling stages.

Supports high-potential therapeutic candidates, to expedite their translation into clinical application for Alzheimer’s disease and related dementia.

This critical phase bridges advanced preclinical work with entry into first-in-human clinical trials.

All therapeutic modalities will be considered, including but not limited to small molecules, PROTACs, antibodies, antisense oligonucleotides (ASOs), gene therapies, and other novel biologics.

Applications may target a wide range of validated or emerging disease mechanisms relevant to Alzheimer’s disease and related dementias, such as amyloid, tau, neuroinflammation, synaptic dysfunction, or other neurodegenerative pathways.